- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Biliary tract cancer
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 880KB)
Durvalumab – March 2023
Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL vial, Solution concentrate for I.V. infusion 500 mg in 10 mL vial; Imfinzi®
Last updated
14 July 2023